人才培育
Yu-Chen Yeh 葉鈺真, R.Ph., M.S.(Associate Director, Pharmerit International) Oscar Liao 廖永良, R.Ph.(Founder, PharmCompass Consulting Ltd.)
活動說明
新藥開發耗時且需要大量資金挹注，藥品的安全性、有效性及品質等方面的要求是取得上市許可的基本門檻，但能否在市場上獲得成功並讓病人使用到此新藥，其中關鍵驅動力則取決於市場進入(market access)，如定價策略及是否可以獲得各國保險給付，以及各醫院或醫師等使用者之使用意願。藥廠需瞭解到各方面利益相關者，如病人、醫師、醫院、保險公司、及政策制定者的需求，並與各利益相關者就產品的臨床及經濟價值進行有效的溝通，方能讓新藥為病人所使用進而取得市場上的利益。
SPARK Taiwan本次邀請到Pharmerit International的Associate Director葉鈺真(Yu-Chen Yeh)及展萃生技顧問的董事總經理廖永良 (Oscar Liao)，分享新藥開發階段的藥品在關鍵市場取得給付的決策流程，以及如何在開發過程中導入market access觀念及做法。歡迎各個SPARK團隊前來參加，讓研發更貼近市場！
Pharmaceutical companies have been increasingly focused on market access strategies given growing cost constraints. Beyond safety, efficacy, and manufacture quality requirements for regulatory approval, reimbursement has become a critical driver to achieve commercial success. Manufacturers must understand the needs of various stakeholders, including patients, clinicians, hospital administrators, payers, and policymakers, and effectively communicate the clinical and economic value of the product with the stakeholders. This seminar will provide an overview of the reimbursement decision-making process in the key markets and address market access planning throughout product development. In addition, tools that can be used to communicate the value of a product will be discussed.